BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25689745)

  • 1. [The SERAPHIN study].
    D'Alto M; Vitulo P
    G Ital Cardiol (Rome); 2015 Jan; 16(1):6-10. PubMed ID: 25689745
    [No Abstract]   [Full Text] [Related]  

  • 2. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM; Channick RN
    Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macitentan (Opsumit) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
    [No Abstract]   [Full Text] [Related]  

  • 4. [Bosentan: a new pillar in the treatment of pulmonary hypertension?].
    Matthes J; Groner F
    Dtsch Med Wochenschr; 2006 May; 131(18):1031-4. PubMed ID: 16673229
    [No Abstract]   [Full Text] [Related]  

  • 5. Changing perceptions in pulmonary hypertension.
    Gerges C; Lang IM
    Lancet Respir Med; 2014 Jan; 2(1):21-3. PubMed ID: 24461891
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pulmonary hypertension].
    Kovacs G; Olschewski H
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2026-8. PubMed ID: 23023615
    [No Abstract]   [Full Text] [Related]  

  • 7. [Opsumit for pulmonary hypertension].
    Sabourin G
    Perspect Infirm; 2014; 11(4):56. PubMed ID: 25269244
    [No Abstract]   [Full Text] [Related]  

  • 8. New answers raise new questions in pulmonary arterial hypertension.
    Kawut SM; Palevsky HI
    Eur Respir J; 2004 Jun; 23(6):799-801. PubMed ID: 15218988
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving survival in pulmonary arterial hypertension.
    Humbert M
    Eur Respir J; 2005 Feb; 25(2):218-20. PubMed ID: 15684283
    [No Abstract]   [Full Text] [Related]  

  • 10. Riociguat recommended by CHMP for approval in the EU for use in two forms of pulmonary hypertension.
    Dowdall M
    Future Cardiol; 2014 Mar; 10(2):163. PubMed ID: 24883440
    [No Abstract]   [Full Text] [Related]  

  • 11. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
    MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study].
    Castro G
    Rev Port Cardiol; 2001 Nov; 20(11):1151-2. PubMed ID: 11826707
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug therapy for pulmonary arterial hypertension: what's on the menu today?
    Mehta S
    Chest; 2003 Dec; 124(6):2045-9. PubMed ID: 14665473
    [No Abstract]   [Full Text] [Related]  

  • 14. Report from the 93rd Cardiovascular and Renal Drugs Advisory Committee Meeting, August 9-10, 2001.
    Fleming T; Lindenfeld J; Lipicky R; Armstrong P
    Circulation; 2001 Oct; 104(15):1742. PubMed ID: 11591605
    [No Abstract]   [Full Text] [Related]  

  • 15. [Targeted therapy of pulmonary arterial hypertension (PAH)].
    Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
    Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
    [No Abstract]   [Full Text] [Related]  

  • 16. Is distal chronic thromboembolic pulmonary hypertension treatable with PAH targeted drugs?
    Cannon JE; Pepke-Zaba J
    Semin Respir Crit Care Med; 2013 Oct; 34(5):620-6. PubMed ID: 24037629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Course of pulmonary artery hypertension disease].
    Hoeper MM
    Krankenpfl J; 2005; 43(4-6):113. PubMed ID: 16171059
    [No Abstract]   [Full Text] [Related]  

  • 18. Building the case for novel clinical trials in pulmonary arterial hypertension.
    Ryan JJ; Rich JD; Maron BA
    Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):114-23. PubMed ID: 25604559
    [No Abstract]   [Full Text] [Related]  

  • 19. Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
    Burger CD
    Ann Am Thorac Soc; 2015 Jun; 12(6):959. PubMed ID: 26075561
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply: Perspectives on Oral Pulmonary Hypertension Therapies Recently Approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Jun; 12(6):960. PubMed ID: 26075562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.